Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836
Dr. Anand Srivastava, Giostar on KUSI NEWs, San Diego, USA.
Mary Seau, sister of San Diego Chargers legend Junior Seau, and Dr. Anand Strvistava joined Good Morning San Diego to talk about how community members are helping to raise money and awareness for CTE research and treatment.
GIOSTAR Chicago to Offer Cutting-Edge Regenerative Therapy Options for a Variety of Musculoskeletal and Degenerative Conditions
CHICAGO, Sept. 7, 2018 /PRNewswire/ — The Global Institute of Stem Cell Therapy and Research (GIOSTAR), the pioneer in regenerative medicine and stem cell-based technologies, announced today the opening of its newest location in Glenview, Illinois at 2614 Patriot Boulevard, Unit A. GIOSTAR Chicago is one of the Institute’s first US facilities, with additional global locations in India, China, Mexico, Thailand, Bangladesh, South Africa, West Africa, Australia and UAE.
GIOSTAR, headquartered in San Diego, California, is an established leader in the field, offering cutting-edge regenerative therapy options for sports injuries, joint arthritis, and additional degenerative conditions. The Institute’s advanced regenerative medicine techniques and protocols have been extensively researched and developed by GIOSTAR’s leading scientists for 20 years. The facility’s team consists of world-renowned authorities in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy, and clinical research.
“Patients at GIOSTAR Chicago can benefit from and depend on safe, extensively researched regenerative cell-based therapies designed to rejuvenate and improve several musculoskeletal injuries and degenerative conditions,” said Shelly Sood, partner, GIOSTAR Chicago. “GIOSTAR’s approach to stem cell therapy is not ‘one size fits all,’ as often seen in other local clinics. We take pride in providing an evidence-based approach, and tailor specific therapies to the individual patient. I am honored to be part of such a world-renowned organization that strives to provide the highest quality standards in health care.”
GIOSTAR’s highly-credentialed team of medical professionals has conducted several clinical trials and been involved with a number of high-profile consultations, including the first clinical trial approved by the US Food and Drug Administration (FDA) using stem cells to treat spinal cord injuries at the University of California, Irvine (UCI) in conjunction with the Christopher & Dana Reeve Foundation in 2007; discussions with renowned physicist Stephen Hawking regarding the effects of stem cell research on Amyotrophic Lateral Sclerosis (ALS); and treatments of former athletes including retired NFL player Wayne Hawkins.
“When we formed GIOSTAR, led by Dr. Anand Srivastava more than a decade ago, our goal was to change the face of medicine by delivering the most advanced, elite and expensive science to the masses around the globe,” said Deven Patel, GIOSTAR’s CEO, and co-founder. “Regenerative medicine is a highly complex field that requires years and years of extensive ongoing research. Most local centers do not fully grasp the nuances and intricacies of this field. They do not have teams of dedicated research scientists conducting ongoing US-based research to enable their centers to continue providing the most advanced science to their patients. At GIOSTAR, we do. I am so thankful to our Institute’s team of renowned scientists and medical professionals for helping us bring our vision to fruition.”
SOURCE GIOSTAR
https://www.giostar.com
http://www.giostarchicago.com
Source : https://goo.gl/CAXLhN
Source : https://www.theintroducermagazine.com/3d-flip-book/the-introducer-volume-7/
Dear Dr. Anand S Srivastava,
Congratulations!
We are very pleased to inform you that your manuscript has successfully gone through all the required processes for publication. Certainly, your article deserves its place on the JSRT’s bookshelf, and we will do our best to share your endeavors with the world. That’s a promise.
Moreover I would like to have your profile in our journal, so I request you to send us your CV at the earliest possibility.
Await your contribution.
Best regards,
Grace Victoria
